Drug Demand Reduction Program (DDRP) Specimen Collection Services
ID: W9133L24R4005Type: Sources Sought
Overview

Buyer

DEPT OF DEFENSEDEPT OF THE ARMYW39L USA NG READINESS CENTERARLINGTON, VA, 22204-1382, USA

PSC

SUPPORT- PROFESSIONAL: OTHER (R499)

Original Source

https://sam.gov/opp/456984b346d3454bb923bbff6836acc4/view
Timeline
    Description

    Sources Sought DEPT OF DEFENSE Drug Demand Reduction Program (DDRP) Specimen Collection Services are being procured by DEPT OF THE ARMY, W39L USA NG READINESS CENTER. This service falls under the SUPPORT- PROFESSIONAL: OTHER industry with PSC code R499. The place of performance for this service is Arlington, VA (zip code 22204), USA. The primary contact for this procurement is Alvaro Pineda, who can be reached at alvaro.l.pineda.civ@army.mil or 7036071218. The description of the service can be found in the attached document titled "Drug Demand Reduction Program".

    Point(s) of Contact
    Alvaro Pineda
    (703) 607-1218
    alvaro.l.pineda.civ@army.mil
    Files
    Title
    Posted
    Attachment 1 PWS DDRP.pdf
    Sources Sought - Drug Demand Reduction Program.pdf
    Lifecycle
    Title
    Type
    Drug Demand Reduction Program (DDRP) Specimen Collection Services
    Currently viewing
    Sources Sought
    Similar Opportunities
    Sources Sought Bulk Sampling and Testing
    Dept Of Defense
    The Defense Logistics Agency (DLA) is seeking contractor support for bulk sampling and testing services to verify the chemical and physical properties of materials entering the National Defense Stockpile. The primary objective of this procurement is to establish independent third-party analytical laboratory services that ensure accurate Certificates of Analysis (COAs) through representative sampling of various materials, including metals and rare earth elements. This initiative is crucial for maintaining high standards in material procurement processes that safeguard national defense interests. Interested vendors must respond to this Sources Sought notice by providing their capabilities and relevant experiences, with the anticipated contract duration of up to 36 months and a budget of up to $9.6 million. For further inquiries, potential contractors can contact Zoryanna Siemer at zoryanna.siemer@dla.mil or Alicia Barrowman at alicia.barrowman@dla.mil.
    Specimen Container Peel Pack
    Dept Of Defense
    The Department of Defense, through the Defense Logistics Agency (DLA) Troop Support, is seeking vendors for the Qualified Suppliers Listing (QSL) for Specimen Container Peel Pack products intended for use in Military Treatment Facilities and operational assemblages. Vendors must possess or apply for a Distribution and Pricing Agreement (DAPA) number, maintain active registration with the System for Award Management (SAM), and have agreements with DoD Medical/Surgical Prime Vendors such as Cardinal Health and Owens & Minor. This initiative is crucial for standardizing medical supplies within the Military Health System, ensuring compliance with quality standards and regulations, including the Trade Agreements Act (TAA). Interested vendors should submit their QSL Package Worksheet and supporting documentation by August 1, 2024, and can direct inquiries to Cornelius Brother at cornelius.l.brothers.ctr@health.mil or Moises Soto at moises.soto1.ctr@health.mil.
    Sources Sought Notice - Cost-Per-Test (CPT) Agreement or Reagent Rental Agreement to include reagents, molecular PCR instrument/equipment, consumables, maintenance support and instrument warranties at BAMC.
    Dept Of Defense
    The Department of Defense, through the Medical Readiness Contracting Office West (MRCO), is seeking potential sources for a Cost-Per-Test (CPT) Agreement or Reagent Rental Agreement to support molecular genetic and infectious disease testing at the Brooke Army Medical Center (BAMC) in Fort Cavazos, Texas. The procurement includes the provision of molecular PCR instruments, reagents, consumables, maintenance support, and instrument warranties, with a base performance period from October 1, 2025, to September 30, 2030. This initiative is critical for enhancing the laboratory's capabilities in conducting various genetic tests, including those for Celiac Disease, Alzheimer’s Disease, and a comprehensive Dermatomycosis Panel, which are essential for informed health assessments and treatment decisions. Interested parties are encouraged to submit their capability statements and relevant information to the primary contact, Medina L. Woodson, at medina.l.woodson.civ@health.mil, by the specified deadlines, as this notice is solely for information and planning purposes and does not constitute a solicitation.
    Request for Information for Radiological Detection System (RDS)
    Dept Of Defense
    The Department of Defense, specifically the Department of the Army, is issuing a Request for Information (RFI) for the development of a Radiological Detection System (RDS) intended to replace existing radiological survey meters used by various military branches. The RFI aims to gather information on the capabilities of potential respondents in developing, testing, and manufacturing an RDS that meets specified performance criteria, with a focus on enhancing radiation detection capabilities across military services and allied nations. Interested parties are required to review the Controlled Unclassified Information (CUI) RDS Performance Specification and submit detailed information regarding their systems’ capabilities, technology proposals, and production capacity by February 17, 2025. For further inquiries, respondents may contact Nathaniel W. Sievers at nathaniel.w.sievers.civ@army.mil or Tyler N. Gates at tyler.n.gates2.civ@army.mil.
    ClonoSEQ Reference Testing Service
    Dept Of Defense
    The Department of Defense, specifically the Department of the Army, is seeking qualified contractors to provide ClonoSEQ Reference Testing Services for the Brooke Army Medical Center (BAMC) located in Fort Cavazos, Texas. The contractor will be responsible for delivering FDA-cleared in vitro diagnostic testing services, specifically the ClonoSEQ® assay, which is crucial for detecting measurable residual disease in patients with certain hematologic malignancies. This procurement is vital for monitoring cancer treatment and ensuring timely processing and reporting of test results, with a contract duration starting from April 1, 2025, to March 31, 2026, and options to extend through March 31, 2029. Interested parties must submit their capability statements by February 7, 2025, and should contact Colleen Rye or Salameya Paulouskaya for further information.
    Alcohol Intervention, WRAIR
    Dept Of Defense
    The Department of Defense, through the Army Medical Research Acquisition Activity, is planning to negotiate a sole source contract with the University of Washington for an alcohol intervention program aimed at addressing alcohol misuse among active-duty military personnel. This initiative is part of the Army’s People First Strategy, which seeks to enhance psychological health and overall readiness by creating healthier environments to mitigate harmful behaviors, including suicide and sexual assault, in light of rising heavy drinking rates among military personnel. The project will focus on developing and assessing a cost-effective and scalable intervention utilizing Personalized Normative Feedback (PNF) to change perceptions about alcohol consumption, ultimately improving medical readiness and mental health. Interested parties may submit their capability information to Nathaniel Reus at Nathaniel.a.reus.civ@health.mil by the specified date, although the government reserves the right to proceed with the sole source contract if no responses are received.
    Sources Sought Notice- DAKO Autostainer Link 48 (Brand Name or Equal)
    Dept Of Defense
    The Department of Defense, through the Medical Readiness Contracting Office - West (MRCO-W), is conducting market research to identify potential sources for the procurement of a Dako Autostainer Link 48 and a PT Link, which must be compatible with Dako Flex RTU kits. The primary objective is to enhance diagnostic capabilities at the Evans Army Community Hospital in Ft. Carson, CO, by acquiring equipment that can detect various histopathologic changes and support specific staining protocols while ensuring FDA compliance. Interested vendors must provide detailed capability statements and relevant organizational information by January 27, 2025, at 10 AM (MST), with submissions directed to Ms. Fabiola Palma-Trujillo and cc'd to Mr. Christopher Gregory via email.
    Dextroamphetamine/Amphetamine National Contract
    Dept Of Defense
    Special Notice DEPT OF DEFENSE Dextroamphetamine/Amphetamine National Contract is a procurement notice from the DEFENSE LOGISTICS AGENCY, specifically the DLA TROOP SUPPORT office. This notice falls under the category of MEDICAL AND SURGICAL INSTRUMENTS, EQUIPMENT, AND SUPPLIES with a PSC code of 6515. The primary contact for this contract is Denise Taubman, who can be reached at DENISE.TAUBMAN@DLA.MIL or 215-737-8677. The notice describes an amendment, P00006, which incorporates additional clauses to the existing contract.
    SPE2D220R0063 BUPROPION XL AMENDMENT 0002
    Dept Of Defense
    Special Notice DEPT OF DEFENSE DEFENSE LOGISTICS AGENCY is seeking BUPROPION XL. This procurement is for drugs and biologicals under PSC code 6505. The primary contact for this procurement is Catherine Gilbert (catherine.gilbert@dla.mil, 2157374778) and the secondary contact is Denise Taubman (denise.taubman@dla.mil, 2157376877). The notice includes Amendment 0002, which incorporates telecommunication clauses. The solicitation is not reopened and the closing date is not extended. BUPROPION XL is typically used for medical purposes.
    Dimethyl Fumarate DR Presolicitation
    Dept Of Defense
    The Defense Logistics Agency (DLA) is planning to issue a solicitation for a national requirements contract for Dimethyl Fumarate DR capsules, specifically 120MG capsules in 14 count bottles and 240MG capsules in 60 count bottles. This procurement aims to establish a reliable national supply source for these pharmaceutical products, which are essential for Department of Defense (DoD) customers through the DLA prime vendor program. The contract will be a firm-fixed price, requirements type contract with a one-year base period and four one-year options, emphasizing compliance with federal regulations and efficient distribution of pharmaceuticals for military healthcare. Interested parties should contact Kevin Rafferty at kevin.rafferty@dla.mil or 215-737-0907 for further inquiries, and the projected solicitation date is February 2021, with an amendment extending the offer submission deadline to October 14, 2021, at 3:00 PM EST.